Interaction of drugs of abuse and microRNA with HIV: a brief review.

Sudheesh Pilakka-Kanthikeel
*Herbert Wertheim College of Medicine, Florida International University, sudheesh.pilakkakanthikeel@fiu.edu*

Madhavan P.N. Nair
*Herbert Wertheim College of Medicine, Florida International University*

Follow this and additional works at: [http://digitalcommons.fiu.edu/com_facpub](http://digitalcommons.fiu.edu/com_facpub)

Part of the [Medicine and Health Sciences Commons](http://digitalcommons.fiu.edu/com_facpub)

Recommended Citation

This work is brought to you for free and open access by the Herbert Wertheim College of Medicine at FIU Digital Commons. It has been accepted for inclusion in HWCOM Faculty Publications by an authorized administrator of FIU Digital Commons. For more information, please contact dcc@fiu.edu.
Interaction of drugs of abuse and microRNA with HIV: a brief review

Sudheesh Pilakka-Kanthikeel * and Madhavan P. N. Nair *

Department of Immunology, Institute of Neuroimmune Pharmacology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA

MicroRNAs (miRNAs), the post-transcriptional regulators of gene expression, play key roles in modulating many cellular processes. The changes in the expression profiles of several specific miRNAs affect the interactions between miRNA and their targets in various illnesses, including addiction, HIV, cancer etc. The presence of anti-HIV-1 microRNAs (which regulate the level of infectivity of HIV-1) have been validated in the cells which are the primary targets of HIV infection. Drugs of abuse impair the intracellular innate anti-HIV mechanism(s) in monocytes, contributing to cell susceptibility to HIV infection. Emerging evidence has implicated miRNAs are differentially expressed in response to chronic morphine treatment. Activation of mu opioid receptors (MOR) by morphine is shown to down regulate the expression of anti-HIV miRNAs. In this review, we summarize the results which demonstrate that several drugs of abuse related miRNAs have roles in the mechanisms that define addiction, and how they interact with HIV.

Keywords: HIV, microRNA, drugs of abuse, cocaine, latency

Introduction

MicroRNAs (miRNAs) are short non-coding regulatory RNAs, approximately 22 nucleotides in length, which bind to the 3’ untranslated regions (UTR) of messenger RNAs (mRNAs) and interfere with their translation, thus contributing to a significant post-transcriptional regulatory step in gene expression (Bartel, 2004; Pilakka-Kanthikeel et al., 2011). One of the important host innate defense mechanisms against retroviruses, such as HIV, is the presence of intracellular viral restriction factors. The micro RNAs belong to this group of “restriction factors.” Over 3000 mature miRNAs have been identified in various species, which highlight their importance in gene regulation. The effect of miRNA can be either direct or indirect. Host cellular miRNA can target host genes/proteins involved in the HIV replication or target viral genes to post transcriptionally silence the protein production. Similarly, viral miRNA (viRNAs) can also either target viral genes, cellular miRNAs or miRNAs. Since their discovery, miRNAs have been linked to biological processes such as drug addiction (He et al., 2010; Zheng et al., 2010), pain perception (Kusuda et al., 2011), neuron development (Gao, 2015), viral infection (Dave and Khalili, 2010; Wang et al., 2011), and opioid receptor regulation (Wu et al., 2008; Sanchez-Simon et al., 2010). Although the mechanisms not completely understood, evidences support the notion that HIV-1 down-regulates some of the cellular anti-HIV-1 miRNAs by inhibiting the proteins involved in its biogenesis and maturation, as a strategy to persist.

HIV latency is a stage in which proviral DNA integrated in to the host's genome does not actively replicate. Even though the mechanisms of establishment and maintenance HIV-1 latency are not completely understood, it is believed to be a multifactorial process involving different cellular and molecular mechanisms. miRNA are also reported to be involved in the maintenance of
HIV latency (Coiras et al., 2009; Van Lint et al., 2013; Battistini and Sgarbanti, 2014). The miRNA expression profiles seem to be modulated in HIV-1-infected cells and in patients. In this review, we summarize the miRNAs that have been reported to be associated with HIV, their change in expression and how the drugs of abuse modulate their expression. mi-RNAs that have been reported to have role in HIV have been summarized in Figure 1. Functions and other details have been discussed in the following sections.

**Cellular Anti-HIV miRNAs in HIV Infection: In vitro Observations**

miRNAs have shown to limit HIV-1 infection by multiple mechanisms. They exhibit cell-type-specific expression and differential expression based on cellular differentiation or activation states contributing to differential cellular susceptibility to HIV-1 infection. This feature led the scientists to focus miRNA as “restriction factor” in the recent past. Few studies have identified cellular miRNAs that target a set of accessory genes of HIV-1 or other host genes/proteins involved in the HIV replication. Lecellier et al. reported for the first time the antiviral activity of cellular miRNAs, where they showed significantly enhanced primate foamy virus type 1 (PFV-1) replication by knock down of miR-32 expression (Lecellier et al., 2005). The initial studies opened an exciting avenue of research exploring how to manipulate endogenous miRNAs and alter cellular susceptibility to HIV-1 infection.

**Anti-HIV miRNAs in CD4⁺ T Cell**

Hariharan et al. using computational approach, predicted five human T-cell miRNAs (miR-29a, miR-29b, miR-149, miR-378 and miR-324-5p) targeting the highly conserved regions across all clades of HIV-1 using computational approach. Among these, miR-29a and miR-29b target the nef gene, whereas miR-149, miR-378, and miR-324-5p target vpr, vif, and vpu respectively (Hariharan et al., 2005). Later Nathans et al. identified 11 miRNAs (miR-29a, 29b, 29c, 149, 147, 138, 513, 516-5p, 581, 644, and 646) that target 3’ UTR of HIV-1 through target prediction analysis of nef, vpr, vif, and vpu (Nathans et al., 2009). They found that the inhibition of miR-29a, b, or c increased HIV-1 production; however, highest effect was associated with miR-29a.

Huang reported five host-coded miRNAs (miR-28, miR-125b, miR-150, miR-151, and miR-106b) that target the 3’UTR of viral mRNAs that inhibit HIV-1 infection (Huang et al., 2007). These anti-HIV miRNAs were differentially expressed in resting vs. active CD4⁺ T cells in-vitro; significantly higher in resting than in activated CD4⁺ T cells. These miRNAs were down-regulated during the activation of resting CD4⁺ T cells, correlating with HIV-1 susceptibility. These cellular miRNAs were thought to be contributing to viral latency observed in quiescent cells. The combination treatment of the five anti-HIV-1 miRNAs inhibitors were more effective in substantially increasing the HIV-1 infection compared to the individual inhibitors in resting CD4⁺ T cells, but not in activated CD4⁺ T cells. These miRNA inhibitors, however, did not affect cellular proliferation status.
miR-125b has been demonstrated to regulate a network of genes in CD4+ T cells that are critical for its differentiation (Rossi et al., 2011), and responsible for latency induction in naive CD4+ T cells (Huang et al., 2007; Wang et al., 2009). Yeung et al. reported a downregulation in miRNA profile (miR-93, miR-148b, miR-221, and miR-16) in HeLa cells after HIV-1 protein expression (Yeung et al., 2005).

miR-27b, miR-29b, miR-150, miR-198, and miR-223 are another group of miRNAs found to be low in resting CD4+ T cells. They seem to be regulating Cyclin T1 protein (Nathans et al., 2009; Chiang et al., 2012), the expression of which is required for transactivation by HIV-1 Tat. CD4+ T cell activation resulted in down-regulation of these miRNAs with a subsequent up-regulation of Cyclin T1, which correlated with enhanced HIV-1 susceptibility. However, miR-198 does not undergo downregulation after T cell activation. It is suggested that a cellular negative-feedback loop is triggered during cyclin T1 upregulation resulting in elevated levels of miR-198 and which in turn result in subsequent dampening of the induction of cyclin T1 (Sung and Rice, 2009). miR-27b also acts in a Cyclin T1-dependent manner, overexpression of which decrease viral replication (Chiang et al., 2012).

A study by Chiang et al. reported a relationship between miR-132 and HIV-1 infection. They found significantly lower miR-132 expression in resting CD4+ T cells than in activated cells. Ectopic expression of miR-132 increased the HIV-1 infection in Jurkat T cells (Chiang et al., 2013), though the exact mechanism behind this effect and the specific step on the viral life cycle that seems to be potentiated by miR-132 are not clear. A probable explanation is that miR-132 overexpression decreases the expression of a cellular protein MeCP2, inhibition of which augments HIV-1 replication (Leoh et al., 2013). However, the precise role of miR-132 and MeCP2 in HIV-1 replication has not been identified. But a study by Desplats et al. reported significantly up-regulated MeCP2 levels in frontal cortex of patients with neurocognitive deficits who had latent HIV-1 infection in the brain (Desplats et al., 2013).

MicroRNAs have also shown to target the receptors and co-receptors needed for HIV entry, thereby restricting the viral entry. Orecchini et al. suggested a mechanism by which Tat manipulate the CD4 receptor, by miR-222 up-regulation (Orecchini et al., 2014). Further studies are warranted in this since the effect of prior induction of miR-222 on viral infection was not investigated by Orecchini et al. Spinello et al. reported a relationship between miR146a and CXCR4 co-receptor. Resting CD4+ T cells have high expression of miR-146a, which was downregulated during their activation by PHA. High expression of miR-146a inhibits the expression of the co-receptor CXCR4, and prevents the HIV entry in U937 and resting CD4+ T cells (Spinello et al., 2011; Quaranta et al., 2015).

Tat exposure significantly up-regulates miR-217 and miR-34a, which bind to the 3’ UTR region of SIRT1 mRNA inhibiting its expression. Lower SIRT1 expression is associated with an enhancement in HIV-1 Tat-mediated transactivation (Zhang et al., 2012a,b). Chaudhuri et al. also demonstrated the functional relevance of cellular miRNAs that target SIRT1 in their simian immunodeficiency virus (SIV) encephalitis study. Post-SIV infection, a significant upregulation of miR-142 was noted that leads to down-regulation of SIRT1, potentially contributing to SIV replication and SIV-induced encephalitis (Chaudhuri et al., 2013). Another study showed significant up-regulation of miR-182 expression by Tat. Higher the miR-182 expression, the lower is the expression of nicotinamide phosphoribosyltransferase (NAMPT), which is a regulator of SIRT1. The down-regulation of NAMPT decreases expression of SIRT1 levels, which in turn enhanced HIV-1 Tat transactivation (Chen et al., 2013).

Anti-HIV miRNAs in Monocyte/macrophage
Monocytes, monocyte derived macrophages (MDM) and monocyte derived dendritic cells (MDDCs) are differentially susceptible to HIV infection. It is suggested that monocyte differentiation and HIV-1 susceptibility are linked by a common set of miRNAs. The five anti-HIV-1 miRNAs (miR-28, miR-125b, miR-150, miR-223, and miR-382), which Huang et al. previously reported, were also highly expressed in monocytes similar to resting CD4 T cells, relating to the refractory nature of monocytes to HIV infection. They showed that level of HIV infectivity was inversely correlated with the level of miRNA expression. These miRNAs were downregulated during the differentiation of monocytes to MDMs (Wang et al., 2009), correlating with the increased susceptibility of macrophages to HIV infection compared to monocytes. Modulating the expression of anti-HIV miRNAs was sufficient to reverse the severity of HIV-1 infection. For e.g., the suppression of these anti-HIV-1 miRNAs in monocytes facilitates HIV-1 infectivity, whereas increase of the antiHIV-1 miRNA expression in macrophages inhibited HIV-1 replication.

However, a subsequent study by Sisk et al. found only miR-223 to be down-regulated during the differentiation of monocytes to MDMs. According to them, the rest of the miRNAs were either higher in MDMs or remain unchanged compared to monocytes (Sisk et al., 2012). The reason for this contradiction is not clear. The different platforms for studying miRNAs, different experimental protocols for the monocyte isolation and/or the monocyte-to-macrophage differentiation, possible alterations in abundance of macrophage subpopulations etc., may have contributed to this difference. Recently, a study by Mestdagh P et al. evaluated the different miRNA quantification platform (Mestdagh et al., 2014).

miR-198 was significantly downregulated upon differentiation of monocytes to macrophages, unlike during T cell activation (Sung and Rice, 2009). miR-198 is shown to be capable of downregulating cyclin-T1 protein expression without affecting cyclin T1 mRNA levels. Low miR-198 expression during macrophage differentiation in turn results in increased Cyclin T1 expression and enhances HIV-1 replication within macrophages (Liou et al., 2002).

Anti-HIV miRNAs on Immune Cell Differentiation
In addition to their direct effect on HIV-1 replication, miRNAs also play significant roles in host innate immune defense regulation. Monocyte differentiation into MDDC is regulated and coordinated by different miRNAs (Wang et al., 2009;
miR-146a and miR-155 are two important miRNAs involved in innate immunity by regulating the acute immune response following toll like receptor (TLR) stimulation. TLR3 and TLR4 ligand [poly(I:C) and LPS] stimulation increase miR-155 in the human monocytic cell line THP1, primary human macrophages (Swaminathan et al., 2012) and in murine bone-marrow-derived macrophages (Taganov et al., 2006; O’Connell et al., 2007). miR-155 participates in the maturation of human dendritic cells (DC) and dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) expression through the transcription factor PU.1 (Martinez-Nunez et al., 2009). DC-SIGN, which binds to the HIV-1 envelope glycoprotein gp120 is important in the process of trans-infection (Geijtenbeek et al., 2000). Since miR-155 decreases DC-SIGN expression, it has been suggested that miR-155 could prevent entry of HIV through DC-SIGN binding (Martinez-Nunez et al., 2009), reducing the HIV infection. The over-expression and inhibition experiments with miR-155 along with TLR3 stimulation demonstrated that miR-155 inhibits HIV-1 at a step prior to the integration of the viral cDNA into the host genome (Swaminathan et al., 2012).

Anti-HIV miRNAs Affect the Expression of HDFs

Certain cellular miRNAs have been shown to inhibit viral replication indirectly through alteration of the levels of certain human proteins, termed “HIV-1 Dependency Factors” (HDFs). Inhibition HDFs has been shown to affect HIV-1 replication (Brass et al., 2008; Goff, 2008).

miR-198 is abundantly expressed in monocytes and miR-27b in resting CD4+T cells. miR-198 and miR-27b reduce cyclin T1 expression thereby inhibiting HIV-1 replication (Sung and Rice, 2009; Chiang et al., 2012). Cyclin T1/CDK9 heterodimer, which form positive elongation factor B (p-TEFb), is a crucial HFD for HIV-1 transcription and translation (Rice and Herrmann, 2003; Hoque et al., 2011). Following monocyte to macrophage differentiation, miR198 expression is decreased and cyclin T1 is expressed at high levels. Sung et al. provided evidence that miR-198 over-expression inhibited HIV-1 replication in macrophages (Sung and Rice, 2009). Chiang et al. later reported that miR-198 is expressed at very low levels in resting CD4+T cells and is not modulated upon activation (Chiang et al., 2012), supporting the concept that miRNAs exert cell-type-specific effects. Triboulet et al. showed that the miRNA cluster miR-17/92 down-regulates p200-CREB binding protein associated factor (PCAF) (Triboulet et al., 2007). PCAF is an important factor for Tat acetylation and HIV-1 LTR-driven transcriptional up-regulation (Deng et al., 2000; D’Orso and Frankel, 2009). Specifically, miR-17-5p and miR-20a over-expression resulted in PCAF inhibition, which is associated with HIV-1 transcription inhibition.

As mentioned in the previous section, miR-155 has been reported to inhibit HIV-1 infection at pre-integration step (Swaminathan et al., 2012). This inhibition is through reduction of the levels of three HDFs: (i) lens epithelial-derived growth factor (LEDFG), (ii) nuclear pore complex protein (Nup)153, and (iii) ADAM10. LEDGF, a cellular cofactor of HIV-1 integrase, promotes viral integration (Ciuffi et al., 2005); Nup153 participates in the nuclear import of the HIV-1 pre-integration complex (Woodward et al., 2009); and ADAM10 facilitate replication at the level of nuclear trafficking (Friedrich et al., 2011). Swaminathan et al. have shown that miR-155 leads to a combined inhibition of these three HDFs, resulting in accumulation of late reverse transcripts and significantly decreasing the viral integration (Swaminathan et al., 2012).

The expression of another well-characterized HDF, purinergic element binding protein a (Pur-a) was reported to be significantly lower in monocytes than in MDDCs, which is assumed to contribute to the lower susceptibility to HIV-1 infection in monocytes (Gallia et al., 1999; Wortman et al., 2000). Certain cellular miRNAs targeting Pur-a mRNA have been identified. Those miRNAs include miR-15a, miR-15b, miR-16, miR-20a, miR-93, and miR-106b, which are highly expressed in monocytes (Shen et al., 2012). The inhibition of these miRNAs increased the Pur-a expression enhancing the HIV-1 infection in monocytes.

Table 1 summarizes the list of cellular miRNAs identified in vitro in relation to HIV/AIDS, the functions of which are discussed in this review.

Anti-HIV miRNAs in HIV Infection in Patient Cohorts

Even though few in vitro reports have been published, only a limited number of studies have been attempted to explore miRNA profiles in HIV-1-infected patients. Houzet et al. was one of the few to report miRNA profiling in patient cohort for the first time (Houzet et al., 2008). They found that compared to uninfected healthy controls, 59 miRNAs were down regulated and 4 miRNAs up-regulated in HIV+ serpositive individuals. Furthermore, T-cell-specific miRNAs miR-150, miR-191, miR-223, miR-16, and miR-146b were down-regulated in all seropositive individuals, when they explored miRNA changes in specific subsets of HIV-1 susceptible cells. Among these, miR-150 and miR-223 are signature anti-HIV-1 miRNAs that have been reported to directly inhibit HIV-1 transcription (Huang et al., 2007). Huang et al. demonstrated an enhancement in HIV-1 production when all five of the “anti-HIV-1 miRNAs” (miR-28, miR-125b, miR-150, miR-223, and miR-382), they identified in vitro were inhibited in resting CD4+ T cells from cART treated patients with undetectable viremia (Huang et al., 2007).

Witwer et al. described the down-regulation of miR-125b, miR-150, and miR-29 in both elite suppressors and viremic patients, compared to uninfected controls (Witwer et al., 2012). miR-155, which inhibit HIV-1 infection in macrophages (Swaminathan et al., 2012), was significantly higher only in viremic patients as compared to ES or healthy controls. miR-9, miR-34a, and miR-181 were up-regulated in viremic patients. In vitro data showing the up-regulation of miR-34a by the Tat, with subsequent down-regulation of SIRT1 and enhanced viral translation supports the increase in miR-34a (Zhang et al., 2012a). In a subsequent study, Witwer et al. found lower miR-125b, miR-31, miR-146b, and miR-29a expression in HIV-1-infected ART naïve patients (Witwer and Clements, 2012).

Frontiers in Microbiology | www.frontiersin.org 4 September 2015 | Volume 6 | Article 967

Plakka-Kanthikeel and Nair Drugs of abuse, miRNA and HIV
<table>
<thead>
<tr>
<th>microRNA</th>
<th>Target</th>
<th>Function</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-29a, miR-29b</td>
<td>Nef</td>
<td>Decrease HIV infection</td>
<td>Coiras et al., 2009; Van Lint et al., 2013</td>
</tr>
<tr>
<td>miR-149</td>
<td>Vpr</td>
<td>Decrease HIV infection</td>
<td>Coiras et al., 2009; Van Lint et al., 2013</td>
</tr>
<tr>
<td>miR-324</td>
<td>Vif</td>
<td>Decrease HIV infection</td>
<td>Coiras et al., 2009; Van Lint et al., 2013</td>
</tr>
<tr>
<td>miR-378</td>
<td>vpu</td>
<td>Decrease HIV infection</td>
<td>Coiras et al., 2009; Van Lint et al., 2013</td>
</tr>
<tr>
<td>miR-29c</td>
<td>3′ UTR</td>
<td>Decrease HIV infection</td>
<td>Van Lint et al., 2013</td>
</tr>
<tr>
<td>miR-149, miR-147, miR-138, miR-513, miR-516, miR-518, miR-581, miR-644, miR-646</td>
<td>3′ UTR</td>
<td>Latency induction in Naïve T-cells</td>
<td>Lecellier et al., 2005</td>
</tr>
<tr>
<td>miR-93, miR-148b, miR-221, miR-16</td>
<td>Cyclin-T1</td>
<td>Decrease HIV infection</td>
<td>Huang et al., 2007</td>
</tr>
<tr>
<td>miR-27b, miR-29b, miR-150, miR-198, miR-223</td>
<td>Decreases MeCP2</td>
<td>Increases HIV infection</td>
<td>Yeung et al., 2005; Chiang et al., 2012</td>
</tr>
<tr>
<td>miR-125b</td>
<td>CD4 receptor</td>
<td>Repress CD4 expression in infected cells</td>
<td>Chiang et al., 2013</td>
</tr>
<tr>
<td>miR-146a</td>
<td>CXCR4</td>
<td>Prevents HIV entry</td>
<td>Desplates et al., 2013; Leoh et al., 2013</td>
</tr>
<tr>
<td>miR-217, miR-34a, miR-142</td>
<td>SIRT1</td>
<td>Increase HIV infection</td>
<td>Spinello et al., 2011; Orecchini et al., 2014; Quaranta et al., 2015</td>
</tr>
<tr>
<td>miR-182</td>
<td>NAMPT, SIRT1</td>
<td>Increase HIV infection</td>
<td>Zhang et al., 2012a</td>
</tr>
<tr>
<td>miR-155</td>
<td>DC-SIGN expression, DC maturation</td>
<td>Reduce HIV infection, Reduce viral integration</td>
<td>Sisk et al., 2012</td>
</tr>
<tr>
<td>miR-17/92, miR-20a, miR-15a, miR-15b, miR-16, miR-20a, miR-92, miR-106b</td>
<td>PCAF</td>
<td>Inhibit HIV replication</td>
<td>Brass et al., 2008</td>
</tr>
<tr>
<td>miR-15a, miR-15b, miR-16, miR-20a, miR-92, miR-106b</td>
<td>Pur-α</td>
<td>Low susceptibility to HIV infection in monocytes</td>
<td>Woodward et al., 2009</td>
</tr>
</tbody>
</table>

Duskova et al. have noted in their study in PBMCs that chronically HIV-1-infected patients have significantly increased miR-19b, miR-146a, miR-615-3p, miR-382, miR-34a, and miR-155 compared to uninfected healthy controls (Duskova et al., 2013).

A study by Bignami et al. found 23 differentially expressed miRNAs between exposed uninfected (EU) and healthy individuals (Bignami et al., 2012). miR-28-5p, miR-125b, and miR-223 were significantly lower in resting CD4+ T cells from EU individuals. Eventhough many miRNAs were differentially expressed between HIV-1 infected patients and EU, Bignami et al. found only miR-155 to be significantly higher in LTNP than in naive HIV-1 patients and MEU (Bignami et al., 2012). Seddiki et al. showed a high expression of miR-155 in effector/memory Tregs compared to both naive Tregs and naive CD4 T cells (Seddiki et al., 2013). Later on, they further found significantly lower expression of miR-9 in CD4+ T cells from chronically infected HIV-1 patients as compared to uninfected healthy individuals or LTNP (Seddiki et al., 2013). The function of miR-9 is to bind to and inhibit the expression of B lymphocyte-induced maturation protein-1 (BLIMP-1). The BLIMP-1 expression was significantly increased in HIV-1 patients, corresponding to the lower level of miR-9, thereby uncovering a potential role for miR-9 in HIV-1-infected patients.

Reynoso et al. described that plasma miRNA profile can discriminate between elite controllers (EC) and chronic HIV infected patients (CH). They found 49 miRNAs differentially expressed between EC from CH, suggesting that higher miRNA present in EC contribute to a successful defense against HIV progression to AIDS compared to CH. The plasma expression levels of miR-29b-3p, miR-33a-5p, and miR-146a-5p were higher in EC than CH, in accordance to recent studies in PBMC. miR-29b-3p is known to target Nef (Ahluwalia et al., 2008) and an association between Nef function and slower progression to AIDS has been established (Cruz et al., 2013). No significant differences were observed between elite controllers and healthy donors; however, 16 miRNAs were different in the plasma of chronic infected vs. healthy donors (Reynoso et al., 2014). miR-18b-5p, miR-126-3p, let-7d-3p, and miR-18a-5p correlated positively and miR-424-5p and miR-34a-5p correlated negatively with CD4+ Tcell counts.

### miRNA in Neuro-AIDS

A subset of individuals infected with HIV-1 develops HIV-associated neurocognitive disorders (HAND) at later stage of the disease even after successful antiretroviral therapy. It is accepted that HAND results from an indirect neurotoxicity, since HIV does not infect neurons in the brain. Activation of
macrophages/microglia is a key player in the development and progression of neuro-AIDS. HIV induced miRNA dysregulation in brain targets diverse biological processes, including neuroinflammation, metabolic processes, and cell death. Micro-RNAs that have been reported in neuroAIDS are listed in Table 2.

Postmortem brains of HIV/SIV-infected humans and monkeys had high miR-21, miR-142-3p, and miR-142-5p (Yelamanchili et al., 2010) compared to uninfected. Myocyte enhancer factor 2C (MEF2C), a CNS transcription factor, is a target of miR-21 in neurons. Repression of MEF2C by miR-21, is a potential pathogenic factor in neurodegenerative disorders such as HAD and HAND (Yelamanchili et al., 2010). Similar to CD4 T cells (Motsch et al., 2007), HIV-1-infected primary human fetal microglia also expresses increased level of miR-146a (Rom et al., 2010) during viral infection. In cultured microglia, a negative correlation exists between miR-146a and monocyte chemotactic protein-2 (MCP-2), which is a ligand for C–C chemokine receptor type 5 (CCR5). i.e., increased expression of miR-146a leads to MCP-2 inhibition. However, they did not find any interference with viral replication with activity of miR-146a.

Six miRNAs (374, 128a, 128b, 100, 25, and 99a) were upregulated and seven miRNAs (let-7e, 298, let-7f, let-7c, let-7b, 320, and 214) were downregulated in rat primary cortical neurons exposed to Tat (Eletto et al., 2008). Tat mediated increase in miR-128a activity in neurons leads to a reduction in synaptosomal-associated protein 25 (SNAP25) expression, a key regulator of membrane fusion (Berkhout, 2008; Eletto et al., 2008). This suggests that Tat-mediated upregulation of miR-128a could lead neuronal damage.

The expression of miR-219, miR-125a, and miR-22 has been reported to be high in HIV or HIV/major depressive disorder (MDD) (Tatro et al., 2010). miR-125a and miR-22 expression in turn leads to decreased protein translation of interferon-induced transmembrane protein 3 (IFITM3), and soluble tumor necrosis factor receptor (sTNFR1A) in primary human neuronal cultures. IFITM protein is shown to inhibit HIV replication (Lu et al., 2011). TNFR1A is involved in neuroinflammation. miR-219 was shown to modulate NMDA receptor-mediated neurobehavioral dysfunction (Kocerha et al., 2009). Noorbakhsh et al. have detected altered expression of miR-129, miR-129-3, and miR-130 in HIV encephalitis (HIVE) brains. Caspase-6, -7, -8, and -9 were associated with multiple miRNAs that were suppressed in HIVE brains (Noorbakhsh et al., 2010).

### Table 2: mi-RNAs in NeuroAIDS.

<table>
<thead>
<tr>
<th>miRNA</th>
<th>Target</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-21</td>
<td>MEF2C</td>
<td>Seddiki et al., 2013</td>
</tr>
<tr>
<td>miR-146a</td>
<td>MCP-2</td>
<td>Cruz et al., 2013</td>
</tr>
<tr>
<td>miR-128a</td>
<td>SNAP25</td>
<td>Yelamanchili et al., 2010; Reynoso et al., 2014</td>
</tr>
<tr>
<td>miR-125a, miR-22</td>
<td>IFITM3, sTNFR1A</td>
<td>Rom et al., 2010</td>
</tr>
<tr>
<td>miR-219</td>
<td>NMDA receptor</td>
<td>Eletto et al., 2008</td>
</tr>
</tbody>
</table>

### Table 3: Drugs of abuse and anti-HIV miRNAs.

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Effect on mi-RNA expression</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morphine</td>
<td>Decrease miR-28, miR-125b, miR-150, miR-382</td>
<td>Wang et al., 2011</td>
</tr>
<tr>
<td></td>
<td>Increase miR-181b</td>
<td>Dave and Khalil, 2010</td>
</tr>
<tr>
<td></td>
<td>Decrease miR-15b</td>
<td>Dhillon et al., 2007</td>
</tr>
<tr>
<td></td>
<td>Decrease miR-155 and miR-20a</td>
<td>Parikh et al., 2014</td>
</tr>
<tr>
<td>Cocaine</td>
<td>Decrease miR-155 and miR-20a</td>
<td>Fiala et al., 2005</td>
</tr>
<tr>
<td></td>
<td>Decrease miR-146a</td>
<td>Kocerha et al., 2009</td>
</tr>
<tr>
<td></td>
<td>Decrease miR-125b</td>
<td>Li et al., 2002</td>
</tr>
<tr>
<td>Methamphetamine</td>
<td>Increase miR-28, miR-125b, miR-150, and miR-382</td>
<td>Shapshak et al., 2011</td>
</tr>
<tr>
<td></td>
<td>No change in miR-296</td>
<td></td>
</tr>
</tbody>
</table>
individuals compared to healthy, non-abusing individuals, corresponding to *in vitro* findings. Another anti-HIV miRNA, miR-223, was not affected by morphine, the reason for which is not clear. In *vivo* investigations using PBMCs from the heroin-dependent subjects also showed the same results for miR-223 expression.

Dave and Khalili reported 26 differentially expressed miRNA in human MDMs treated with morphine; with miR-15b expression showing greatest increase and miR-181b greatest decrease (Dave and Khalili, 2010). Morphine induces inflammation and oxidative stress in immune cells through regulating the miR-15b and 181b, thereby contributing to the AIDS progression.

Drugs of abuse have shown to upregulate the expression of CXCR4, which facilitate the entry of HIV into CD4+ T cells resulting in increased infection of X4-tropic HIV-1 (Steele et al., 2003). We, in our preliminary *in vitro* experiments saw that cocaine down-regulated miR146a thereby increasing CXCR4 expression (Pilakka-Kanthikeel et al., 2012). We have also shown that cocaine and morphine significantly down-regulated miR-155 and miR-20a in MDDC, thereby enhancing the HIV-1 infectivity. Cocaine or morphine induced effect on HIV infectivity was reversed by transfection of MDCC with miR155 mimic (Napuri et al., 2012, 2013).

miR-125b is a member of anti-HIV-1 miRNA family that targets the 3'-UTR of HIV-1 transcripts and inhibit viral translation, a post entry step (Rossi et al., 2011). Cocaine, was also shown to inhibit miR-125b in CD4+T cells, which in turn enhances HIV-1 replication (Mantri et al., 2012). The overexpression of miR-125b decreases HIV-1 replication, suggesting a key role for miR-125b in the cocaine-induced enhancement of HIV-1 replication in CD4+T cells.

METH has been shown to increase HIV-1 replication in various HIV-1 permissive cells, including dendritic cells (DCs) (Nair et al., 2009) and monocye-derived macrophage (Liang et al., 2008). Toussi et al. showed enhancement of HIV-1 replication of R5 tropic JR-CSF HIV-1 in human CD4+T cells and in the peripheral CD4+T cells of JR-CSF/hu-CycT1 HIV-1 transgenic mouse, with METH treatment upto 150 mmol/L (Toussi et al., 2009). In contrast to these reports, a recent study by Mantri et al. showed that METH inhibits HIV-1 replication by up-regulating the cellular anti-HIV-1 miRNAs (miR-28-5p, miR-125b, miR-150, and miR-223) in primary CD4+T cells (Mantri et al., 2014). The expression of the anti-viral miR-296-5p was not affected by METH in primary CD4+T cells.

**Conclusion and Future Directions**

Taken together, the present findings suggest that cell type specific expression of intracellular anti-HIV miRNAs play a role in making cells more or less susceptible to HIV infection. miRNAs have been suggested to play role in maintaining the HIV latency, the transition from latency to activation, the reduction of virion production etc. However, the interaction of the host miRNA with HIV-1 is still at a budding stage. A complete cure for HIV-1 is possible only when HIV-1 gene is silenced or completely eliminated from every latently infected cell. Identifying the role of miRNAs associated with HIV-1 latency could help in developing new strategies to intervene the mechanism of viral persistence. Also, more studies on the impact of drugs of abuse on anti-HIV miRNA expression, and strategies to block their effect on miRNA expression will help in developing therapeutics for drug addiction by manipulating the actions of miRNA.

An interesting avenue for future research that has not yet been explored is to investigate if HIV-1 modulates the expression of cellular miRNAs that can alter the expression of restriction factors. Interestingly, miR-181 (miR-181- ab,c and -d) has been predicted to bind to and potentially inhibit the HIV-1 restriction factor sterile alpha motif and histidine/aspartic acid domain-containing protein 1 (SAMHD1). We and another group recently showed miR181a and miR-155 regulate SAMHD1 (Jin et al., 2014; Pilakka-Kanthikeel et al., 2015a,b). Earlier, Gottwein et al. reported a viral miR-K12-11, an ortholog of cellular miR-155, to target SAMHD1 (Gottwein et al., 2007). More studies are warranted to study the role of miRNAs that regulate the HIV restriction factors and how drugs of abuse interact with them.

**Acknowledgments**

This work was supported partly by grants from National Institutes of Health (R37DA025576, R03DA037782) and Pilot grant (80004604) from the Florida International University Foundation.

**References**


**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2015 Pilakka-Kanthikeel and Nair. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.